NEW YORK – Pan-cancer responses to the MEK inhibitor binimetinib (Pfizer/Array Biopharma's Mektovi) can vary depending on the NRAS codon that is altered, according to findings from a Phase II basket trial presented at the American Association for Cancer Research's Virtual Annual Meeting this week.